share_log

Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Kelly James Patrick

Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Kelly James Patrick

诺瓦瓦克斯医药 | 4:持股变动声明-高管 Kelly James Patrick
美股SEC公告 ·  01/04 06:43

Moomoo AI 已提取核心信息

James Patrick Kelly, EVP, CFO and Treasurer of Novavax, is set to execute a planned stock transaction on 12/31/2024. Kelly will exercise options to acquire 35,000 shares of common stock at no cost, then immediately sell 16,906 shares at $8.04 per share to cover tax liabilities.The total value of the disposed shares amounts to $135,924.24. Following these transactions, Kelly's direct ownership in Novavax will increase to 32,602 shares. This pre-arranged transaction aligns with the company's executive compensation structure and tax obligation management practices.Investors should note that this future transaction is part of a planned executive stock option exercise and does not necessarily reflect the CFO's view on the company's current valuation or future prospects.
James Patrick Kelly, EVP, CFO and Treasurer of Novavax, is set to execute a planned stock transaction on 12/31/2024. Kelly will exercise options to acquire 35,000 shares of common stock at no cost, then immediately sell 16,906 shares at $8.04 per share to cover tax liabilities.The total value of the disposed shares amounts to $135,924.24. Following these transactions, Kelly's direct ownership in Novavax will increase to 32,602 shares. This pre-arranged transaction aligns with the company's executive compensation structure and tax obligation management practices.Investors should note that this future transaction is part of a planned executive stock option exercise and does not necessarily reflect the CFO's view on the company's current valuation or future prospects.
诺瓦瓦克斯医药的执行副总裁、首席财务官兼财务主管詹姆斯·帕特里克·凯利计划于2024年12月31日进行一项股票交易。凯利将行使期权,以无成本获得35,000股普通股,然后立即以每股8.04美元卖出16,906股以覆盖税务负债。处置的股票总价值达到135,924.24美元。完成这些交易后,凯利在诺瓦瓦克斯医药的直接持股将增加至32,602股。这项预先安排的交易与公司的高管薪酬结构和税务义务管理实践一致。投资者应注意,此次未来交易是计划中的高管股票期权行使,并不一定反映首席财务官对公司当前估值或未来前景的看法。
诺瓦瓦克斯医药的执行副总裁、首席财务官兼财务主管詹姆斯·帕特里克·凯利计划于2024年12月31日进行一项股票交易。凯利将行使期权,以无成本获得35,000股普通股,然后立即以每股8.04美元卖出16,906股以覆盖税务负债。处置的股票总价值达到135,924.24美元。完成这些交易后,凯利在诺瓦瓦克斯医药的直接持股将增加至32,602股。这项预先安排的交易与公司的高管薪酬结构和税务义务管理实践一致。投资者应注意,此次未来交易是计划中的高管股票期权行使,并不一定反映首席财务官对公司当前估值或未来前景的看法。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息